What does ProteinQure do?
ProteinQure is a biotechnology company focused on developing computational peptide therapeutics using its proprietary ProteinStudio platform. This platform integrates machine learning, structural biology, and atomic-level simulations to design precision peptides that enable tissue-specific delivery and target classes across oncology, neurology, nephrology, and rare diseases.
How much did they raise?
The company raised $11M in Series A financing, led by Tom Williams of Heron Rock Fund, with participation from Golden Ventures and Kensington Capital, bringing its total funding to $16M.
What are their plans for the money?
With the new funds, ProteinQure plans to initiate its first clinical trial for PQ203, a first‐in‐class peptide-drug conjugate for triple-negative breast cancer, and further advance its pipeline in neurology and nephrology, potentially opening up new treatment avenues.
What have they achieved so far?
ProteinQure has already made significant strides with its ProteinStudio platform, which has enabled the design of precision therapeutic peptides and demonstrated potential across multiple challenging treatment areas.
